Just because some tech investors got caught up in the hype doesn’t mean it was a real technical risk. Finger capillary blood is fundamentally unrepresentative

Just because some tech investors got caught up in the hype doesn’t mean it was a real technical risk. Finger capillary blood is fundamentally unrepresentative of blood samples taken from veins with few exceptions. Doctors and scientists have known this for a long time. Theranos’ technology was never going to work the way they sold it, and if they sold it as a faster on-site diagnostic device with standard blood draws they would have been just another in a sea of diagnostics startups that few care about.